Roche announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with aromatase inhibitors (AI) for the adjuvant treatment of HR+/HER2-II and III high-risk early-stage breast cancer patients, including N0 patients.
诺华集团：凯丽隆获美FDA批准用于治疗HR+/HER2-早期乳腺癌
Roche: Kisqali approved by the US FDA for the treatment of HR+/HER2- early-stage breast cancer
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated